TIO Bioventures

Treadwell Therapeutics Inc. is a clinical-stage oncology company focused on developing innovative therapeutics to meet unmet medical needs in cancer treatment. Founded in 2019 in New York, the company has a robust pipeline that includes several promising candidates, such as CFI-400945, a first-in-class PLK4 kinase inhibitor, and CFI-402257, a best-in-class TTK inhibitor. Additionally, Treadwell is advancing CFI-402411, an oral immunomodulatory kinase inhibitor targeting HPK1. The company also boasts a diverse pre-clinical pipeline featuring multiple biologic and next-generation TCR-based autologous cell therapy programs. With a commitment to exploiting cancer cell vulnerabilities, Treadwell Therapeutics aims to enhance recovery for patients through its innovative drug development efforts.

TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption seeks to develop a pipeline of product candidates that can treat cancer type and patient populations that are underserved by current approaches.